Local Open-label Multicenter Study to Evaluate the Quality of Life in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to DMARDs When Adding Tocilizumab (TCZ).
Phase of Trial: Phase IV
Latest Information Update: 13 Jun 2015
At a glance
- Drugs Tocilizumab (Primary) ; Disease-modifying antirheumatics
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms LORNET
- Sponsors Roche
- 07 Jun 2017 Biomarkers information updated
- 13 Jun 2015 Results presented at the 16th Annual Congress of the European League Against Rheumatism.
- 16 Mar 2012 Actual number of patients changed from 195 to 201 as reported by ClinicalTrials.gov.